수술을 위해 FVIII 치료가 필요한 혈우병 A가 있는 여성/소녀의 관리에서 Nuwiq 투여 및 결과
수술을 위해 FVIII 치료가 필요한 혈우병이 있는 여성/소녀의 관리에서 Nuwiq 투여 및 결과 - 국제, 공개 라벨, 비대조 연구(NuDIMENSION)
Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 4단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Cristina Solomon
- 전화번호: +41795859042
- 이메일: cristina.solomon@octapharma.com
연구 장소
-
-
-
Bonn, 독일
- 모병
- Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin
-
Duisburg, 독일
- 모병
- Gerinnungszentrum Rhein-Ruhr
-
Hamburg, 독일
- 모병
- Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik
-
-
-
-
Texas
-
San Antonio, Texas, 미국, 78229
- 모병
- UT Health San Antonio
-
-
-
-
-
Belgrade, 세르비아
- 모병
- Clinical Center for Serbia
-
-
-
-
-
Bern, 스위스
- 모병
- Insel Spital Bern
-
-
-
-
-
Madrid, 스페인
- 모병
- Hospital Universitario la Paz
-
Seville, 스페인
- 모병
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Leeds, 영국
- 모병
- St. James's University Hospital
-
-
-
-
-
Montevideo, 우루과이
- 아직 모집하지 않음
- Centro Hospitalario Pereira Rossell
-
-
-
-
-
Catanzaro, 이탈리아
- 모병
- Aziendo Ospedaliera "Puglieze Ciaccio"
-
Palermo, 이탈리아
- 모병
- Policlinico "P. Giaconne"
-
-
Trentino-Alto Adige
-
Trento, Trentino-Alto Adige, 이탈리아
- 모병
- Santa Chiara Hospital - APSS
-
-
-
-
-
Chambray-lès-Tours, 프랑스
- 모병
- Avenue de la République
-
Nantes, 프랑스
- 모병
- CHU de Nantes Hôtel-Dieu
-
Strasbourg, 프랑스
- 모병
- Chu de Strasbourg
-
-
-
-
-
Helsinki, 핀란드
- 모병
- Helsinki University Hospital,Coagulation Disorder Unit
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Women/girls with haemophilia A (FVIII:C ≥1-<40%) according to medical history. Additionally, women/girls with documented FVIII activity levels between ≥ 40% and 50% may be included if there is a documented history of clinically significant bleeding episodes consistent with haemophilia A; and/or either documented prior treatment with FVIII concentrates or a clinical indication that FVIII treatment would have been appropriate (e.g., use of FVIII from a family member, or treatment with alternative haemostatic agents due to access limitations)
- At least 12 years of age
- Scheduled to undergo major surgery* requiring FVIII treatment, including elective and emergency procedures and caesarean section in pregnant women with haemophilia A
- Freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations
Exclusion Criteria:
- Coagulation disorder other than haemophilia A
- Present or past FVIII inhibitor (≥0.6 Bethesda units [BU]/mL)
- Severe liver or kidney disease (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels >5 times the upper limit of normal; or creatinine >120 μmol/L)
- Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
- Pregnancy, except in participants with a planned caesarean section
- Already had surgery in this study
- Current participation in another interventional clinical trial
- Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Nuwiq
All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL. |
Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall haemostatic efficacy
기간: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Overall haemostatic efficacy of treatment measured as binary "success" or "failure". The overall perioperative haemostatic efficacy of Nuwiq will be adjudicated by an Independent Data Monitoring Committee (IDMC) and determined using a composite assessment algorithm that considers the surgeon's assessment of intraoperative haemostatic efficacy and the investigator's assessment of postoperative haemostatic efficacy to classify the overall haemostatic efficacy as success or failure. |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Intraoperative haemostatic efficacy
기간: During surgery: From first skin incision to last suture
|
Assessment of intraoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: Intraoperative blood loss was lower than or equal to the average expected blood loss for the type of procedure performed in a patient with normal haemostasis and of the same sex, age, and stature Good: Intraoperative blood loss was higher than the average expected blood loss but lower or equal to the maximal expected blood loss for the type of procedure in a patient with normal haemostasis. Moderate: Intraoperative blood loss was higher than the maximum expected blood loss for the type of procedure performed in a patient with normal haemostasis, but haemostasis was controlled. None: Haemostasis was uncontrolled, necessitating a change in the clotting factor replacement regimen. |
During surgery: From first skin incision to last suture
|
|
Postoperative haemostatic efficacy
기간: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Assessment of postoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: No postoperative bleeding or oozing that was not due to complications of surgery. All postoperative bleeding (due to complications of surgery) was controlled with Nuwiq as anticipated for the type of procedure. Good: No postoperative bleeding or oozing that was not due to complications of surgery. Control of postoperative bleeding due to complications of surgery required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. Moderate: Some postoperative bleeding and oozing that was not due to complications of surgery. Control of postoperative bleeding required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. None: Extensive uncontrolled postoperative bleeding and oozing. |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
|
Allogenic blood products
기간: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Use of allogeneic blood products (red blood cells, platelets, and other blood products) |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
|
FVIII plasma levels
기간: ≤30 minutes before and 15-30 minutes after Nuwiq injection
|
Perioperative plasma levels |
≤30 minutes before and 15-30 minutes after Nuwiq injection
|
|
Perioperative haemostatic efficacy per WFH criteria
기간: ≤30 minutes before and 15-30 minutes after Nuwiq injection
|
Assessed using 4-point scale recommended by WFH: Excellent: Intra- and post-operative blood loss similar to non-haemophilic patient. No extra doses of FVIII/bypassing agents needed Good: Intra- and/or post-operative blood loss slightly increased over expectation for non-haemophilic patient, but judged to be clinically insignificant. No extra doses of FVIII/bypassing agents needed Fair: Intra- and/or post-operative blood loss increased over expectation for the non-haemophilic patient, and additional treatment needed. Extra dose of FVIII/bypassing agents needed, or increased blood component of anticipated transfusion requirement Poor: Significant intra- and/or post-operative blood loss substantially increased over expectation for non-haemophilic patient, requires intervention not explained by medical issue other than haemophilia. Unexpected hypotension, unexpected transfer to ICU due to bleeding, substantially increased blood component of the anticipated transfusion requirement |
≤30 minutes before and 15-30 minutes after Nuwiq injection
|
|
Adverse events
기간: From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of adverse events recorded during the full study period |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
|
Thrombotic events
기간: From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of thrombotic events during the study |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
|
FVIII inhibitor formation
기간: From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of FVIII inhibitor formation |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Johannes Oldenburg, Experimental Haematology and Transfusion Medicine, University Clinic Bonn
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GENA-23
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .